NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Multiple Technology Appraisal (MTA)

Etanercept, abatacept, adalimumab and tocilizumab for treating juvenile idiopathic arthritis (including review of TA35)

Please sign and return via NICE Docs/Appraisals.

I confirm that:

- I agree with the content of the submission made by **The Royal College of Pathologists** and consequently I will not be submitting a personal statement.

Name: [redacted]

Signed:

Date: 04/06/2015